ATP3 Women

Estimates a woman’s 10‑year risk of hard coronary heart disease using modified Framingham ATP III factors.

Age
20-34-735-39-340-44045-49+350-54+655-59+860-64+1065-69+1270-74+1475-79+16
Tot Chol
<160 (4.1) & Age 20-790160-199 (4.1-5.3) & Age 60-69+1160-199 (4.1-5.3) & Age 70-79+1200-239 (5.3-6.2) & Age 70-79+1160-199 (4.1-5.3) & Age 50-59+2200-239 (5.3-6.2) & Age 60-69+2240-279 (6.2-7.3) & Age 70-79+2280+ (7.3+) & Age 70-79+2160-199 (4.1-5.3) & Age 40-49+3240-279 (6.2-7.3) & Age 60-69+3160-199 (4.1-5.3) & Age 20-39+4200-239 (5.3-6.2) & Age 50-59+4280+ (7.3+) & Age 60-69+4240-279 (6.2-7.3) & Age 50-59+5200-239 (5.3-6.2) & Age 40-49+6280+ (7.3+) & Age 50-59+7200-239 (5.3-6.2) & Age 20-39+8240-279 (6.2-7.3) & Age 40-49+8280+ (7.3+) & Age 40-49+10240-279 (6.2-7.3) & Age 20-39+11280+ (7.3+) & Age 20-39+13
Smoker
Nonsmoker & Age 20-790Smoker & Age 70-79+1Smoker & Age 60-79+2Smoker & Age 50-59+4Smoker & Age 40-49+7Smoker & Age 20-39+9
HDL
60+ (1.6+)-150-59 (1.3-1.6)040-49 (1.0-1.3)+1<40 (1.0)+2
Syst BP
<1200120-129 & Untreated+1130-139 & Untreated+2120-129 & Treated+3140-159 & Untreated+3130-139 & Treated+4160+ & Untreated+4140-159 & Treated+5160+ & Treated+6

Indicazioni d'uso

Used in asymptomatic women to estimate 10‑year hard CHD risk (MI or CHD death) and guide intensity of lipid‑lowering therapy. Applies to women without existing CHD or CHD risk equivalents (e.g., diabetes) and uses traditional Framingham variables for primary‑prevention decisions 1 [Level II evidence]. Clinical utility: stratifies into <10%, 10–20%, or >20% CHD risk to determine LDL‑C treatment thresholds and need for statin therapy 2 [Level III evidence].

Approfondimenti e precauzioni

Start with recognition that it underestimates total CVD risk in women, because it predicts only hard CHD events and misses stroke and revascularization, which are more common in women 1 [Level III evidence]. It ignores female‑specific risks (e.g., adverse pregnancy outcomes, premature menopause) and does not incorporate hsCRP, which markedly improves long‑term prediction in women 2 [Level I evidence]. It may misclassify many younger women as low risk despite substantial lifetime risk.